Focus: Impact Therapeutics is a Shanghai-based small-molecule biotech focused on oncology, infectious diseases, hematology, and neurology. The company is in Series C+ stage with 80 active job openings, indicating active growth and expansion.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Hot — 51 jobs added in 30d
Net +22 (51 new, 29 removed). Aggressive expansion phase.
Impact Therapeutics is a growth-stage oncology biotech with a credible Phase 3 candidate and expanding team, but career risk hinges on cash runway and execution against a crowded immuno-oncology landscape.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Impact Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Impact Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo